Oliveira Frick Vilma, Rubie Claudia, Ghadjar Pirus, Faust Sabrina K, Wagner Mathias, Gräber Stefan, Schilling Martin K
Department of General, Visceral, Vascular and Pediatric Surgery, University of the Saarland, Building 57, Homburg/Saar 66421, Germany.
Tumour Biol. 2011 Feb;32(1):189-96. doi: 10.1007/s13277-010-0112-y. Epub 2010 Sep 24.
Chemokines have been proposed to contribute to tumour growth and metastatic spread of several cancer entities. Here, we examined the relative levels of CXCL12/CXCR4 in resection specimens from patients with different malignant and non-malignant colorectal diseases as well as colorectal liver metastases (CRLM). CXCL12/CXCR4 mRNA and protein expression profiles were assessed by quantitative real-time PCR, Western blot analysis, enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry in resection specimens from patients with ulcerative colitis (UC; n = 15), colorectal adenoma (CRA; n = 15), colorectal adenocarcinoma (CRC; n = 47) and CRLM (n = 16). Corresponding non-affected tissues served as control. In contrast to UC tissues, CXCL12 showed a distinct down-regulation in CRA, CRC and CRLM specimens, whereas the corresponding receptor CXCR4 demonstrated a significant up-regulation in CRC and CRLM related to corresponding non-affected tissues (p < 0.05, respectively). Our results strongly suggest an association between CXCL12/CXCR4 expression and the induction of CRA, CRC and the development of CRLM. Therefore, CXCR4 may be a potential target for specific therapeutic interventions.
趋化因子被认为与多种癌症实体的肿瘤生长和转移扩散有关。在此,我们检测了不同恶性和非恶性结直肠疾病患者以及结直肠癌肝转移(CRLM)患者切除标本中CXCL12/CXCR4的相对水平。通过定量实时PCR、蛋白质印迹分析、酶联免疫吸附测定(ELISA)和免疫组织化学,对溃疡性结肠炎(UC;n = 15)、结直肠腺瘤(CRA;n = 15)、结直肠癌(CRC;n = 47)和CRLM(n = 16)患者的切除标本中CXCL12/CXCR4 mRNA和蛋白表达谱进行了评估。相应的未受影响组织作为对照。与UC组织相比,CXCL12在CRA、CRC和CRLM标本中表现出明显下调,而相应的受体CXCR4在CRC和CRLM中相对于相应的未受影响组织表现出显著上调(分别为p < 0.05)。我们的结果强烈表明CXCL12/CXCR4表达与CRA、CRC的诱导以及CRLM的发生之间存在关联。因此,CXCR4可能是特定治疗干预的潜在靶点。